BioArctic Neuroscience is a research company developing new drugs and diagnostics for neurodegenerative disorders. In 2007, a license agreement was signed with Eisai Co., Ltd., Japan, regarding an antibody treatment (BAN2401) for Alzheimer’s disease.
The antibody project is now being run toward clinical trials and commercialization. BioArctic will be responsible for marketing in the Nordic region. The collaboration with Eisai and the initiation of new projects mean that BioArctic needs to recruit additional scientists to the company.